Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2017-08-30 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
国金证券股份有限公司关于公司使用部分闲置募集资金暂时补充流动资金事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Guojin Securities Co., Ltd. regarding the use of idle raised funds by Ruikang Pharmaceutical Co., Ltd. to temporarily supplement working capital. It references specific approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange regulations, details about non-public stock issuance in 2012 and 2015, and the company's compliance with relevant laws and procedures. The document is a formal verification or audit opinion on the use of funds, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion but rather an audit or verification opinion on a specific financial matter. The document length is under 5,000 characters and is focused on the audit/verification of fund usage, fitting the category of Audit Report / Information (AR). FY 2017
2017-08-30 Chinese
第三届董事会第九次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting, specifically the third session of the third board's ninth meeting. It includes details about the meeting date, voting results, and decisions such as the temporary use of idle raised funds to supplement working capital and the scheduling of an extraordinary general meeting. There is no detailed financial data or comprehensive report content. The document is a formal announcement of board decisions, not a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1053 characters), and it is clearly a meeting resolution announcement rather than a report or regulatory filing.
2017-08-30 Chinese
第三届监事会第六次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a resolution passed by the Supervisory Board (监事会) of 瑞康医药股份有限公司 regarding the temporary use of idle raised funds to supplement working capital. It includes details of the meeting, voting results, and compliance with relevant regulations. The document is short (1096 characters) and serves as a public notice of a board decision related to capital usage, not a full financial report or detailed financial data. It is an announcement about capital/financing activities, specifically the use of raised funds, which fits the Capital/Financing Update (CAP) category. It is not an Annual Report, Interim Report, or Audit Report, nor is it a regulatory filing or a report publication announcement. Therefore, the best classification is CAP with high confidence.
2017-08-30 Chinese
关于继续使用部分闲置募集资金临时性补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding the continued use of idle raised funds to temporarily supplement working capital. It includes historical context of previous uses of raised funds, approvals from the board and supervisory committees, independent directors' opinions, and the sponsor's opinions. The document references regulatory approvals and compliance with securities regulations. It is not a full financial report, audit report, or earnings release. It is not a presentation or transcript. The document is a formal announcement about the use of capital raised through non-public stock issuance, specifically about the use of idle raised funds to supplement working capital temporarily. This fits the category of Capital/Financing Update (CAP), as it updates on the company's use of fundraising proceeds and capital structure usage. The document length is substantial and contains detailed information, not just a brief notice or a report publication announcement. Therefore, the best classification is CAP with high confidence.
2017-08-30 Chinese
独立董事关于公司募集资金使用相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from the independent directors of a company regarding the use of idle raised funds to temporarily supplement working capital. It references regulatory guidelines and internal governance rules but does not contain financial statements or detailed financial data. The document is short (800 characters) and serves as a formal opinion or statement related to capital use rather than a full financial report or announcement of voting results. It is not a report publication announcement since it contains substantive content, but it is also not a full financial report like an Annual Report or Interim Report. The content aligns best with a Capital/Financing Update (CAP) as it discusses the use of raised funds and financing matters.
2017-08-30 Chinese
国金证券股份有限公司关于公司非公开发行限售股份上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Guojin Securities Co., Ltd. regarding the listing and circulation of restricted shares from a non-public issuance by Ruikang Pharmaceutical Co., Ltd. It includes specific information about the non-public issuance, shareholding changes, lock-up periods, shareholder commitments, and the approval and compliance with relevant securities regulations and stock exchange rules. The document is a formal verification and opinion letter from the sponsor institution confirming the compliance and approval of the restricted shares' circulation. It does not contain financial statements, earnings data, or management discussion but focuses on the regulatory compliance and share circulation verification. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance and verification announcement related to share circulation, not a financial report or announcement of voting results or capital changes.
2017-08-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.